IL1RL1 and inflammatory bowel disease: Aberrant expressions of IL-33 and/or ST2 has been well documented in plentiful inflammatory disorders, such as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease (37).